Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation

Fig. 2

Number of CTCs during treatment with BRAF/MEK inhibitors. MMbraf1, MMbraf2, MMbraf3, and MMbraf4 were diagnosed with metastatic BRAFv600E/K melanoma. a Monitoring the number of CTCs during the clinical course in MMbraf1. The graph shows the number of CTCs and the LDH level (upper limit of normal, 230 IU/L). Arrows indicate lung metastases in computed tomography (CT) imaging. b Monitoring the number of CTCs during the clinical course in MMbraf2. Circles indicate a right axillary lymph node (LN) metastasis in CT imaging. c Monitoring the number of CTCs during the clinical course in MMbraf3. Arrowheads indicate a liver metastasis in CT imaging. d Monitoring the number of CTCs during the clinical course in MMbraf4. Arrows indicate a right inguinal LN metastasis in CT imaging

Back to article page